- Company
- Samsung BioLogics acquired all of its shares in Epis
- by Chon, Seung-Hyun Apr 24, 2022 06:33pm
- Samsung BioLogics will incorporate Samsung Bioepis as a 100% subsidiary and operate a separate management system. Samsung BioLogics announced on the 20th that it has completed the first payment of $1 billion in the acquisition of Epis shares to Biogen. From the day the first payment was completed under the contract between the two companies,
- Company
- Tecentriq, first immunotherapy reimbursed in liver cancer
- by jung, sae-im Apr 22, 2022 06:07am
- Roche’s Tecentriq(atezolizumab) became the first cancer immunotherapy to be approved for reimbursement in liver cancer. Analysts have assessed that it had prepared the footsold to expand its sales with the first expansion in its scope of reimbursement in 3 years since 2019. Tecentriq is continuing its stride to overcome the stronghold of Ke
- Company
- The opinions of the pharmaceutical community vary widely
- by jung, sae-im Apr 22, 2022 06:07am
- Employees of pharmaceutical companies who have entered the era of post-COVID-19 due to the end of social distancing are divided. Various opinions are coming out as it is divided into pharmaceutical companies that maintain telecommuting and pharmaceutical companies that terminate. Pros and cons also followed group meetings such as company dinn
- Company
- Companies are struggling with the form of post-COVID-19 work
- by Apr 20, 2022 06:06am
- As social distancing measures are lifted in two years, changes are also detected in the pharmaceutical industry. However, telecommuting is unlikely to disappear immediately. As more and more conferences attempt online and offline hybridization this year, they are also cautious about overseas business trips. ◆ Maintaining voluntary work
- Company
- Homegrown Rosuzet·K-CAB sell over ₩10 bil a month
- by Chon, Seung-Hyun Apr 20, 2022 06:05am
- New drugs developed by Korean pharmaceutical companies are showing strength in the prescription market. Hanmi Pharmaceutical’s Rosuzet and HK Inno. N’s K-CAB has recorded over &8361;10 billion in monthly sales and made a good start. According to the market research institution UBIST on the 19th, the hyperlipidemia treatment Lipitor record
- Company
- 1 in 3 don't know the right dose of antipyretic drugs
- by Apr 20, 2022 06:05am
- With COVID-19, 9 out of 10 consumers have purchased antipyretic drugs within the past six months, but one in three still does not know the appropriate dosage, indicating that appropriate medication guidance is needed. Johnson & Johnson Korea announced the results of a survey conducted on 1,000 consumers aged 20 to 49 in Korea on the 18th through
- Company
- Hanmi leads the outpatient prescription market in Q1 2022
- by Chon, Seung-Hyun Apr 19, 2022 05:53am
- Hanmi Pharmaceutical’s performance stood out in the outpatient prescription market with its solidified lead heralded by the introduction of its new combination drug. Daewon Pharmaceutical’s prescription volume has also soared vertically due to the boom in anti-inflammatory and cold medicines following a surge in the number of confirmed COVID-1
- Company
- The prolonged slump in IPO of pharmaceutical bio
- by Kim, Jin-Gu Apr 19, 2022 05:52am
- Amid the prolonged sluggish trend in the IPO market in the pharmaceutical bio industry, attention is being paid to whether newly challenged companies will be able to draw a turnaround. According to the pharmaceutical industry on the 19th, there are two pharmaceutical bio companies that have been listed in the second quarter of this year, Wont
- Company
- Pharmaceutical industry starts face-to-face marketing
- by Kim, Jin-Gu Apr 18, 2022 05:58am
- As the government decided to completely lift social distancing measures from today (18th), the pharmaceutical bio industry is also actively planning offline marketing events. As large-scale offline events have been virtually impossible for nearly two years, marketers are raising expectations for changes caused by the move. ◆ Abolish so
- Company
- DHP Korea faces reimb. reevaluations for its HA eye drops
- by Nho, Byung Chul Apr 18, 2022 05:58am
- How DHP Korea, a company specializing in eye drops, will be establishing a strategy to defend its sales ahead of the upcoming reimbursement reevaluations for its HA (hyaluronic acid) products next year is drawing attention. In particular, this upcoming risk is highly likely to serve as a testbed to verify the company’s newly appointed CEO Eu
